Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 53.16M | 55.57M | 60.09M | 63.29M | 67.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 206.23M | 218.08M | 236.16M | 240.60M | 264.54M |
| Operating Income | -206.23M | -218.08M | -236.16M | -240.60M | -264.54M |
| Income Before Tax | -212.72M | -222.34M | -236.80M | -236.17M | -251.91M |
| Income Tax Expenses | 30.00K | 55.00K | 130.00K | 130.00K | 183.00K |
| Earnings from Continuing Operations | -212.75 | -222.39 | -236.93 | -236.30 | -252.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -212.75M | -222.39M | -236.93M | -236.30M | -252.09M |
| EBIT | -206.23M | -218.08M | -236.16M | -240.60M | -264.54M |
| EBITDA | -206.19M | -218.03M | -235.95M | -240.24M | -264.06M |
| EPS Basic | -1.23 | -1.33 | -1.45 | -1.46 | -1.57 |
| Normalized Basic EPS | -0.75 | -0.81 | -0.89 | -0.89 | -0.98 |
| EPS Diluted | -1.23 | -1.33 | -1.45 | -1.46 | -1.57 |
| Normalized Diluted EPS | -0.75 | -0.81 | -0.89 | -0.89 | -0.98 |
| Average Basic Shares Outstanding | 695.39M | 671.92M | 653.50M | 645.96M | 643.70M |
| Average Diluted Shares Outstanding | 695.39M | 671.92M | 653.50M | 645.96M | 643.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |